Acute graft-versus-host disease (GvHD) remains a serious complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). To date, corticosteroids are the accepted first-line therapy, however are only effective in approximately half of all patients with ~50% of cases going on to develop steroid-refractory GvHD, which leads to increased non-relapse mortality rates. Thus, there is an unmet need for development of novel treatment strategies for acute GvHD to improve post-transplant outcomes. Please see the current novel therapy options in the downloadable table below: